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E-mail address: inabipour@gmail.com (I. NabipourObjective: It has been suggested that adipose-derived cytokines act as insulin sensitizers/insulin-mimet-
ics and some others may induce insulin resistance. In order to elucidate the potential role of novel adi-
pocytokines in the pre-diabetes states, circulating levels of novel adipocytokines were evaluated in
ﬁrst-degree relatives of subjects with type 2 diabetes mellitus (FDRs).
Method: Serum omentin-1, adiponectin and retinol-binding protein 4 (RBP4) levels were measured in
179 subjects (90 glucose tolerant FDRs and 89 age- and sex-matched healthy controls) using enzyme-
linked immunosorbent assay (ELISA) methods.
Results: There was no signiﬁcant difference between the twogroups regarding serumRBP4 concentrations.
However, serum omentin-1 (median [interquartile range], 6.18 [4.06–11.52] ng/ml versus 10.50 [4.30–
20.60] ng/ml, p = 0.004) and adiponectin (mean ± SD, 10.07 ± 4.0 lg/ml versus 20.66 ± 8.12 lg/ml,
p < 0.0001) levels were signiﬁcantly lower in FDRs when compared with the controls. In multiple logistic
regression analysis, FDRs showed a signiﬁcant associationwith lower circulating omentin-1 and adiponec-
tin levels, even after adjustments were made for age, sex, body mass index, blood pressure measures, and
biochemical parameters including glucose status, lipid proﬁle, insulin levels and HOMA-IR (OR = 0.49, CI
[0.30–0.79]; p = 0.004 and OR = 0.74, CI [0.67–0.82]; p < 0.0001, respectively). However, FDRs did not show
a signiﬁcant association with serum RBP4 levels in different models of regression analyses.
Conclusions: The FDRs showed signiﬁcant associations with lower omentin-1 and adiponectin levels. A
potential role for these adipokines in the FDRs’ increased risk of diabetes needs to be further elucidated.
 2012 Elsevier Ltd. All rights reserved.1. Introduction Omentin-1 is a novel 34 kDa adipokine that is highly and selec-It has been suggested that adipose-derived cytokines act as a
potential link between energy homeostasis, immunity, neuroendo-
crine, atherosclerosis, type 2 diabetes, and insulin resistance [1–4].
Several of these bioactive mediators that are collectively called
‘adipocytokines’ may be considered insulin sensitizers/insulin-
mimetics, and some others may induce insulin resistance [5].ll rights reserved.
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).tively expressed in visceral adipose tissue compared with subcuta-
neous adipose tissue [6,7]. Furthermore, omentin-1 enhances
insulin action and Akt phosphorylation [7]; it is inversely related
to obesity [8] and is down regulated by insulin and glucose [9].
Adiponectin is the most abundant adipocytokine with insulin
sensitizing, anti-inﬂammatory, and anti-atherogenic effects [1,4].
Adiponectin levels have inverse correlations with dyslipidemia,
atherosclerosis, glucose intolerance, and insulin resistance in
diverse patient populations [1,3]. In fact, hypoadiponectinemia
has been suggested as one of the most important adipocytokines
in the pathogenesis of type 2 diabetes [1].
The serum levels of retinol-binding protein 4 (RBP-4) reﬂect the
risks of impaired glucose tolerance and type 2 diabetes [10].
The link between elevated RBP-4 levels and impaired insulin secre-
tion has been shown in insulin resistant humans with obesity,
impaired glucose tolerance and type 2 diabetes, and even in lean
Table 1
The general characteristics, including blood pressure and anthropometric measure-
ments, and the biochemical parameters of ﬁrst-degree relatives of subjects with type
2 diabetes mellitus (FDRs) and healthy controls.
FDRs (n = 90) Control (n = 89) p Value
Female/male ratio 49/41 40/49 0.233
Age (years) 40.55 ± 9.63 41.37 ± 9.47 0.575
Systolic BP (mmHg) 115 ± 13.8 115.82 ± 12.84 0.687
Diastolic BP (mmHg) 74.72 ± 9.95 74.45 ± 10.47 0.864
WHR 0.90 ± 0.14 0.91 ± 0.17 0.511
BMI (kg/m2) 27.57 ± 4.25 26.52 ± 4.24 0.104
Fasting glucose (mg/dl) 80.5 ± 8.56 79.77 ± 10.46 0.612
2 h-OGTT (mg/dl) 92.17 ± 15.68 92.03 ± 16.65 0.956
Total cholesterol (mg/dl) 198.54 ± 36.85 196.92 ± 37.24 0.770
Triglyceride (mg/dl) 155.72 ± 82.3 155.52 ± 75 0.279
HDL-cholesterol (mg/dl) 43 ± 10.38 45.44 ± 11.65 0.140
LDL-cholesterol (mg/dl) 121.01 ± 31.55 120.04 ± 32.44 0.840
Insulin (lIU/ml) 8.75 (5.25–16.68) 6.56 (5.03–10.18)* 0.027
HOMA-IR 1.82 (1.05–3.06) 1.29 (0.98–1.93)* 0.010
Omentin-1 (ng/ml) 6.18 (4.06–11.52) 10.50 (4.30–20.60) 0.004
RBP4 (lg/ml) 100.0 ± 42.73 95.28 ± 55.34 0.535
Adiponectin (lg/ml) 10.07 ± 4.0 20.66 ± 8.12 <0.0001
BMI, body mass index; WHR, waist to hip ratio; BP, blood pressure; 2 h-OGTT,
second-hour oral glucose tolerance test; HOMA-IR, homeostasis model of assess-
ment index; RBP4, retinol-binding protein 4.
Data are means (SD), except for insulin and HOMA-IR, and omentin-1 which are
medians (interquartile ranges).
* p values <0.05 (the FDRs in comparison to the controls).
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betes [3,4,11,12].
Although adipokines may be involved in the pathogenesis of
diabetes mellitus and insulin resistance, the contributions of indi-
vidual adipokines to the pathophysiological features of insulin
resistance and/or insulin sensitivity must still be fully clariﬁed.
First-degree relatives of subjects with type 2 diabetes mellitus
(FDRs) frequently have insulin resistance [13]. The results of a large
population study [14] showed that b cell impairment exists in the
offspring of type 2 diabetes patients, even in the absence of insulin
resistance. Thus, b cell dysfunction is the outstanding determinant
for the development of diabetes mellitus in this group.
FDRs bear a 40% lifetime risk for developing type 2 diabetes
mellitus [15]. The background of insulin resistance/b cell dysfunc-
tion and glucose metabolism in FDRs used to assess the circulating
levels of novel adipocytokines such as omentin, RBP-4 and adipo-
nectin may be helpful in illustrating some pathophysiological as-
pects of adipose tissue involvement in the development of
insulin resistance in this group. In the present study, we performed
the ﬁrst evaluation of serum omentin in addition to assessing RBP-
4 and adiponectin levels in FDRs, matching control subjects with-
out a family history of type 2 diabetes mellitus.
2. Methods
2.1. Subjects and physical measurements
Ninety normoglycemic subjects (mean age ± SD 40.55 ±
9.36 years: 41 men and 49 women) who were ﬁrst-degree relatives
of patients with type 2 diabetes mellitus (FDRs) and who consecu-
tively visited the Endocrine Clinic at Fatemeh-Zahra University
Hospital were enrolled in this study. The age and sex-matched con-
trols (41.375 ± 9.47 years: 49 men, 40 women) were selected from
a cohort of healthy subjects recruited by the Persian Gulf Healthy
Heart Study at Bushehr University of Medical Sciences [16] for
evaluation of cardiovascular risk factors in the Persian Gulf region.
The following criteria were used for the healthy controls: (1) they
had no family history of diabetes mellitus, type 2 diabetes or endo-
crine disorders, cardiovascular diseases, or hepatic or renal
dysfunction; (2) they had no history of taking antidiabetic and
antiobesity drugs, glucocorticoids, anti-inﬂammatory agents,
estrogenic or androgenic medications.
The participants in the control group had anthropometric mea-
surements comparable to those of the FDRs (Table 1). All subjects
were asked to fast and to present to the Persian Gulf Health
Research Center between 7:30 and 9:30 a.m. They underwent a
75-g oral glucose tolerance test (OGTT). The deﬁnition of glucose
tolerance was a subject who had a fasting plasma glucose level
lower than 110 mg/dl and a second-hour blood sugar level after
oral glucose load (2 h-OGTT) lower than 140 mg/dl [17].
Blood pressure was assessed twice at the right arm after a
15 min rest in the sitting position, using a standard mercury sphyg-
momanometer. Height and weight were measured using a stadi-
ometer. Heavy outer garments and shoes were removed before
height and weight were measured. Body mass index (BMI) was
calculated. Waist circumference was deﬁned at the midway level
between the costal margins and the iliac crests. Hip circumference
was measured at the level of the greater trochanters. Waist-to-hip
ratio was calculated for all participants.
The study was approved by the Medical Ethics Committee of
Bushehr University of Medical Sciences.
2.2. Laboratory measurements
A fasting blood sample was taken, all samples were promptly
centrifuged, and sera were separated and kept frozen at 70 Cuntil they were used. Analyses for biochemical parameters (blood
glucose, triglyceride, and cholesterol levels) were carried out at
the Persian Gulf Health Research Center on the day of blood collec-
tion using a Selectra 2 autoanalyzer (Vital Scientiﬁc, Spankeren,
The Netherlands). Glucose was assayed with the enzymatic (glu-
cose oxidase) colorimetric method using a commercial kit (Pars
Azmun Inc., Tehran, Iran). Serum total cholesterol and HDL (high-
density lipoprotein) cholesterol were measured using cholesterol
oxidase phenol aminoantipyrine and triglycerides using the glyc-
erol-3 phosphate oxidase phenol aminoantipyrine enzymatic
method. Serum LDL (low-density lipoprotein) cholesterol was
calculated using the Friedwald formula. LDL cholesterol was not
calculated when the triglycerides concentration was >400 mg/dl.
Insulin was measured using a commercially available enzyme-
linked immunosorbent assay kit (Insulin ELISA, DRG Diagnostics,
Marburg, Germany). The assay sensitivity was 1.76 lIU/ml; the in-
tra- and inter-assay coefﬁcients of variance were 1.79–2.6% and
2.88–5.99%, respectively.
Insulin resistance was assessed by calculating the homeostasis
model of assessment index (HOMA-IR) using the following equa-
tion: fasting insulin (lIU/ml)  fasting glucose (mg/dl)/405.
Serum omentin-1 concentrations were measured using manual
omentin-1 (human) detection (ELISA kit [intelectin-1 (human)
ELISA kit, Apotech Corporation, Switzerland]). The detection limit
of the assay was 0.4 ng/ml (range 0.5–32 ng/ml). The mean intra-
assay and inter-assay CVs of the omentin-1 assay were 4.51–7.4%
and 4.19–9.27%, respectively. The antibodies used in this kit are
speciﬁc to the measurement of natural and recombinant human
omentin-1.
To detect adiponectin in the serum samples, commercially (Cat.
No. AG-45A-0001EK-KI01) available enzyme-linked immunosor-
bent assay kits (AdipoGen, Incheon, Korea) were used according
to the manufacturer’s instructions. The limit of detection of the
assay was 100 pg/ml; the intra- and inter-assay coefﬁcients of var-
iance were 2.9–3.8% and 2.8–5.5%, respectively.
For the detection of RBP4 in the serum samples, commercially
available ELISA (AdipoGen, Incheon, Korea) kits were used accord-
ing to the manufacturer’s instructions. The assay sensitivity was
Table 2
Unadjusted and adjusted odds ratios [OR; 95% conﬁdence interval (CI)] between the
S. Akbarzadeh et al. / Cytokine 58 (2012) 295–299 297380 pg/ml; the intra- and inter-assay coefﬁcients of variance were
1.7–3.7% and 5.9–8.8%, respectively.presence of ﬁrst-degree relatives of subjects with type 2 diabetes mellitus (FDRs) and
circulating adipocytokines (omentin-1, RBP4, and adiponectin) levels.
OR CI p Value
Omentin-1
Unadjusted 0.50 0.33–0.75 0.001
Adjusted for age + sex 0.49 0.32–0.74 0.001
Adjusted for age + sex + BMI 0.50 0.33–0.77 0.001
Adjusted for age + sex + WHR 0.49 0.32–0.79 0.001
Full model 0.49 0.30–0.79 0.004
RBP4
Unadjusted 1.0 0.99–1.0 0.533
Adjusted for age + sex 1.0 0.99–1.0 0.395
Adjusted for age + sex + BMI 1.0 0.99–1.0 0.450
Adjusted for age + sex + WHR 1.0 0.99–1.0 0.435
Full model 1.0 0.99–1.01 0.561
Adiponectin
Unadjusted 0.77 0.71–0.83 <0.0001
Adjusted for age + sex 0.75 0.69–0.82 <0.0001
Adjusted for age + sex + BMI 0.75 0.69–0.83 <0.0001
Adjusted for age + sex + WHR 0.76 0.69–0.82 <0.0001
Full model 0.74 0.67–0.82 <0.0001
BMI, body mass index; WHR, waist to hip ratio.
Full model included age, sex, BMI, systolic and diastolic blood pressures, HOMA-IR,
fasting glucose, second-hour blood glucose, insulin, triglyceride, HDL-cholesterol,
and LDL-cholesterol levels.2.3. Statistical analysis
Normal distribution of the data was controlled with the
Kolmogorov–Smirnov test. Probability values <5% were considered
statistically signiﬁcant. The signiﬁcance of the difference in the
results between the two groups was determined with chi-square
analysis using 2  2 contingency tables. A two-tailed t-testwasused
to compare the values across groups in the presence of a normal dis-
tribution. Signiﬁcant differences were assessed with the Mann–
Whitney U test in the absence of a normal distribution. Analysis of
variance (ANOVA) was performed to test differences in adipokines
across quartiles of measures of obesity and HOMA-IR.
Because the distributions of serum insulin levels, HOMA-IR and
omentin-1 were skewed, logarithmically transformed values for
HOMA-IR and natural logarithmically transformed values for
omentin-1 were used for statistical analysis.
Multiple linear regression models were used to assess age- and
sex-adjusted associations of serum omentin-I, adiponectin and
RBP4 levels in relation to anthropometric and blood pressure mea-
surements as well as biochemical variables in both the FDRs and
the healthy controls.
Binary logistic regression analysis was used to ascertain the
associations between the presence of FDRs and circulating adipo-
cytokines (omentin-1, adiponectin, and RBP4) levels. In the full
model, the presence of FDRs versus healthy controls was the
dependent variable. Age, sex, BMI, systolic and diastolic blood
pressures, HOMA-IR, fasting glucose, second-hour blood glucose,
insulin, triglyceride, HDL-cholesterol and LDL-cholesterol levels,
and circulating adipocytokines were considered covariates.
All statistical analyses were performed using the PASW Statis-
tics GradPack 18 (SPSS Inc., Chicago, IL).3. Results
The characteristics of the study participants are shown in
Table 1. There were no signiﬁcant differences in age, gender, blood
pressure measurements, height, weight, waist and hip circumfer-
ences, waist to hip ratio, and BMI between the FDRs and the con-
trols. There was also no signiﬁcant difference in the fasting blood
glucose, 2 h-OGTT, and lipid proﬁles between the two groups.
However, the FDRs had higher HOMA-IR and serum insulin levels
than the control group (p < 0.05, Table 1).
The serum levels of the studied adipocytokines of the FDRs and the
healthycontrols are also shown inTable1. Therewasno signiﬁcantdif-
ferencebetweenthe twogroups regardingserumRBP4concentrations.
However, serum omentin-1 (median [interquartile range], 6.18 [4.06–
11.52] ng/ml versus 10.50 [4.30–20.60] ng/ml, p = 0.004) and adipo-
nectin levels (mean ± SD, 10.07 ± 4.0 lg/ml versus 20.66 ± 8.12 lg/
ml, p < 0.0001) were signiﬁcantly lower in the FDRs when compared
with the controls. No gender difference was found for the circulating
omentin-1, adiponectin and RBP4 levels (p > 0.05).
Age- and sex-adjusted serum omentin-1, adiponectin and RBP4
levels had no correlations with anthropometric and blood pressure
measurements, fasting blood glucose, 2 h-OGTT, triglyceride, total
cholesterol, HDL-cholesterol, LDL-cholesterol, insulin, and HOMA-
IR in the FDRs and the healthy controls (p > 0.05, data not shown).
Furthermore, the age- and sex-adjusted adipokines serum levels
showed no linear correlations with each other.
The studied population was divided into quartiles of BMI, WHR,
and HOMA-IR. There were no signiﬁcant differences across
quartiles of BMI for omentin-1, adiponectin, and RBP4 levels. The
results did not change after stratifying the studied groups by sex.There were no signiﬁcant differences across quartiles of WHR
for omentin-1, and adiponectin levels. However, circulating RBP4
showed a signiﬁcant difference across WHR quartiles (p = 0.033).
Compared with subjects in the lowest quartile of WHR, those in
the highest quartile had a signiﬁcantly higher means of RBP4
(111.61 ± 49.27 lg/ml versus 79.88 ± 50.52 lg/ml, p = 0.007).
Analysis by quartiles of HOMA-IR revealed an inverse signiﬁ-
cant association with serum levels of adiponectin (p = 0.011). Com-
pared with subjects in the lowest quartile of HOMA-IR, those in the
highest quartile had a signiﬁcantly lower means of serum adipo-
nectin (12.67 ± 7.77 lg/ml versus 16.85 ± 9.33 lg/ml, p = 0.027).
However, analysis by quartiles of HOMA-IR did not reveal signiﬁ-
cant associations with serum levels of RBP4 and in omentin-1.
The results did not change after stratifying the studied groups by
sex.
Table 2 shows unadjusted and adjusted odds ratios (95% CI) be-
tween the presence of FDRs and circulating adipocytokines levels.
In multiple logistic regression analysis, the FDRs showed a signiﬁ-
cant association with lower circulating omentin-1 and adiponectin
levels, even after adjustments were made for age, sex, BMI, blood
pressure measures and biochemical parameters including glucose
status, lipid proﬁle, insulin levels, and HOMA-IR (OR = 0.49, CI
[0.30–0.79]; p = 0.004 and OR = 0.74, CI [0.67–0.82]; p < 0.0001,
respectively). However, the FDRs did not show a signiﬁcant associ-
ation with serum RBP4 levels in different models of regression
analyses (Table 2).
4. Discussion
In the current study, we found that the FDRs had a signiﬁcant
association with lower omentin-1 and adiponectin levels, even
after adjusting for age, sex, BMI, and biochemical parameters in
multivariate analyses. However, no signiﬁcant difference was
found in serum RBP4 concentrations between the FDRs and the
controls.
Omentin-1 is a newly identiﬁed depot-speciﬁc adipokine in hu-
man adipose tissue that may modulate insulin sensitivity by its
paracrine or endocrine functions [7]. It has been shown that omen-
tin-1 levels were inversely correlated with measures of obesity and
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els [8]. Expression of omentin-1 mRNA and protein levels are de-
creased in polycystic ovary syndrome, which is associated with
obesity and insulin resistance [9]. It is interesting that circulating
omentin-1 concentrations increased after weight loss and with
improvement of insulin sensitivity [18]. Aerobic training in over-
weight and obese men was accompanied by increased omentin-1
concentrations [19]. It has been reported that omentin-1 levels
were lower in patients with metabolic syndrome than in the con-
trols [20].
The results of these studies conﬁrm that omentin-1 may con-
tribute to the underlying pathophysiology of insulin resistance.
Impaired glucose metabolism is common in FDRs [13]. They
also have defects in b cell function when they are not hyperglyce-
mic, and this reduction affects insulin and amylin responses to glu-
cose stimulation [21]. Since both insulin sensitivity and b cell
dysfunction predict conversion to diabetes [14,22], FDRs are at in-
creased risk of type 2 diabetes [15]. Therefore, they are very good
available models to study the early development of insulin resis-
tance in a pre-diabetes state.
In the current study, we observed for the ﬁrst time that circulat-
ing omentin-1 levels were lower in FDRs than the controls. How-
ever, decreased omentin mRNA expression levels were reported
in patients with type 2 diabetes and obesity [23]. In two recent
studies, serum omentin levels were lower in patients with type 2
diabetes and impaired glucose regulation than in the normal glu-
cose tolerance group [24,25].
In the current study, the observed reduced levels of omentin-1
may suggest a potential role for this adipocytokine in the FDRs’ in-
creased risk of type 2 diabetes.
RBP4 is a newly discovered adipokine and was suggested as a
potential link with type 2 diabetes mellitus by Yang et al. [11].
They showed that serum RBP4 levels were elevated in GLUT4 glu-
cose transporter knockout mice and humans with obesity and type
2 diabetes [11]. Currently, increasing evidence denotes an associa-
tion between increased circulating levels of RBP4 with type 2 dia-
betes mellitus and/or insulin resistance states [11,25,12,26–31]. A
pathophysiological link between RBP4 and type 2 diabetes mellitus
may also arise from impaired insulin secretion [3]. By evaluation of
insulin secretion, insulin sensitivity, insulin disposition index and
serum RBP4 in non-diabetic men within a wide range of obesity,
Broch et al. suggested that RBP4 may impact b-cell secretion [32].
Only two studies evaluated circulating RBP4 levels in FDR. In one
of these studies, the authors found that RBP4 correlated inversely
with the rate of glucose disposal and correlated positively with fast-
ing insulin levels amongnon-obese, normoglycemic subjectswith at
least one ﬁrst-degree relative with type 2 diabetes [12]. In the sec-
ond study, serum RBP4 levels were reported to be signiﬁcantly ele-
vated in the normoglycemic FDR group compared with the control
group [33]. In contrast to these studies, we found no signiﬁcant dif-
ference for circulating RBP4 levels between the FDR and the control
group. The discrepancies with these two studies of our obtained re-
sults cannot be explained until the results of larger studies are avail-
able. However, differences in the selection and the characteristics of
the studied populations, including the use of different measuring
systems, may be potential contributing factors.
Reduced adiponectin mRNA in subcutaneous adipose tissue was
reported in FDRs by Lihn et al. [34]. Accordingly, they suggested
that adiponectin gene expression is dysregulated in FDR. Similar
to our ﬁnding, Pellme et al. reported that plasma adiponectin levels
were decreased in non-obese but insulin-resistant FDR [35]. Skele-
tal muscle adiponectin receptors gene expression levels, as well as
plasma adiponectin concentration were reported to be lower in
subjects with a family history of type 2 diabetes than in those with
no family history of the disease. In addition, there was a positive
correlation between adiponectin receptors gene expression levelsin skeletal muscles and insulin sensitivity [36]. Reduced circulating
adiponectin levels were also reported in lean and normoglycemic
offspring of type 2 diabetic subjects [37,38]. In a cross-sectional
study among healthy Korean men and women, lower serum adipo-
nectin levels were associated with a family history of diabetes
independently of obesity and insulin resistance [39]. Recently, it
has been shown that the FDR group had lower adiponectin levels
versus the normal group at baseline, and these levels were reduced
in both groups over a ﬁve year period [40].
Together these observations support the concept that adiponec-
tin may play a role in the development of insulin resistance in FDR.
Although we found that there were no linear correlations be-
tween these novel adipokines and BMI or WHR, the studied sub-
jects who had the fourth quartile of WHR showed higher RBP4
levels compared with those in the ﬁrst quartile of WHR. However,
the medical literature is inconsistent in the correlations between
circulating adipokines and obesity measurements. In our study,
the lack of strong linear correlations between the indices of obesity
and these novel adipokines could be caused by the small number of
participants and narrow range of adiposity measures among the
studied population. Furthermore, the subjects of our study were
healthy, except for the positive family history of type 2 diabetes
in the FDR group. However, substantial studies about adipokines
in relationship to obesity were conducted among subjects with
glucose intolerance, type 2 diabetes mellitus, polycystic ovary syn-
drome, non-fatty liver disease or the metabolic syndrome.
Likewise, age- and sex-adjusted omentin-1, RBP4 and adipokine
levels showed no correlations with HOMA-IR in the FDR and con-
trol groups. However, circulating adiponectin levels were lower
in the fourth quartile of HOMA-IR than in the ﬁrst quartile of
HOMA-IR. Several studies have conﬁrmed correlations between
insulin sensitivity, circulating adiponectin [41,42], RBP4 [2,11],
and omentin-1 [13], but these associations may be more detectable
in clamp-derived indices of insulin sensitivity than HOMA-derives
indices, which are less sensitive [2].
We acknowledge several study limitations. As our data are
cross-sectional, limited inferences can be made regarding tempo-
rality and causation. In the current study, insulin sensitivity with
the gold-standard isoglycaemic–hyperinsulinemic clamp test was
not measured; however, good correlations between HOMA-IR
and insulin resistance assessed by some ‘‘gold standard’’ methods
have been reported [43]. Another limitation of our study includes
the lack of assessment of b cell function. Since we assessed the
investigated adipocytokines with single measurements, the
changes in these adipocytokines over time could not be reﬂected
in the current study.
In conclusion, FDRs had signiﬁcantly reduced levels of omentin-
1 and adiponectin levels compared with the control subjects, but
they had similar circulating levels of RBP4. The observed lower lev-
els of omentin-1 and adiponectin in the FDR group were indepen-
dent of metabolic and biochemical variables. The physiologic and
pathophysiologic contribution of these ﬁndings remains to be ex-
plained but may indicate a pathophysiological role for omentin-1
and adiponectin in the FDRs who bear a high lifetime risk for devel-
oping type 2 diabetes mellitus.
To clarify the role of circulating adipocytokines in relation to the
worsening of glucose tolerance over time in FDRs, longitudinal
studies with concurrent measurements of additional adipocyto-
kines, inﬂammatory markers and cytokines would elucidate the
complex system that regulates beta cell function and insulin sensi-
tivity in pre-diabetes states.Conﬂict of interest
None of the authors has the conﬂicting ﬁnancial interest.
S. Akbarzadeh et al. / Cytokine 58 (2012) 295–299 299Acknowledgments
This study was supported in part by a grant from Bushehr Prov-
ince Technology and Research Committee and Research Deputy of
Bushehr University of Medical Science.
References
[1] Gulcelik NE, Usman A, Gurlek A. Role of adipocytokines in predicting the
development of diabetes and its late complications. Endocrine 2009;36:
397–403.
[2] Perseghin G, Lattuada G, De CobelliF F, et al. Serum retinol-binding protein-4,
leptin, and adiponectin concentrations are related to ectopic fat accumulation.
J Clin Endocrinol Metab 2007;92:4883–8.
[3] Esteve E, Ricart W, Fernandez-Real JM, et al. Adipocytokines and insulin
resistance. the possible role of lipocalin-2, retinol binding protein-4, and
adiponectin. Diabetes Care 2009;32:S362–7.
[4] Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol
Med 2008;14:741–51.
[5] Kralisch S, Bluher M, Paschke M, et al. Adipokines and adipocyte targets in the
future management of obesity and the metabolic syndrome. Mini Rev Med
Chem 2007;7:39–45.
[6] Schafﬂer A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C.
Genomic structure of human omentin, a new adipocytokine expressed in
omental adipose tissue. Biochim Biophys Acta 2005;1732:96–102.
[7] Yang RZ, Lee MJ, Hu H, et al. Identiﬁcation of omentin as a novel depot-speciﬁc
adipokine in human adipose tissue: possible role in modulating insulin action.
Am J Physiol Endocrinol Metab 2006;290:E1253–61.
[8] de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene
expression are decreased in obesity. Diabetes 2007;56:1655–61.
[9] Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased
in overweight insulin-resistant women with polycystic ovary syndrome:
ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes
2008;57:801–8.
[10] Cho YM, Youn BS, Lee H, et al. Serum retinol-binding protein-4 concentrations
are elevated in human subjects with impaired glucose tolerance and type 2
diabetes. Diabetes Care 2006;29:2457–61.
[11] Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes
to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–62.
[12] Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin
resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:
2552–63.
[13] Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C,
et al. Early metabolic defects in persons at increased risk for non-insulin-
dependent diabetes mellitus. N Engl J Med 1989;321:337–43.
[14] Stadler M, Pacini G, Petrie J, Luger A, Anderwald C. RISC Investigators. b cell
(dys)function in non-diabetic offspring of diabetic patients. Diabetologia
2009;52:2435–44.
[15] Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean
nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes
1997;46:1001–9.
[16] Nabipour I, Amiri M, Imami SR, Jahfari SM, Shafeiae E, Nosrati A, et al. The
metabolic syndrome and nonfatal ischemic heart disease; a population-based
study. Int J Cardiol 2007;118:48–53.
[17] Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The
signiﬁcance of impaired fasting glucose versus impaired glucose tolerance.
Importance of insulin secretion and resistance. Diabetes Care 2003;26:1333–7.
[18] Moreno-Navarrete JM, Catalan V, Ortega F, et al. Circulating omentin
concentration increases after weight loss. Nutr Metab (Lond) 2010;7:27.
[19] Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum
omentin-1 and cardiometabolic risk factors in overweight and obese men. J
Sports Sci 2010;28:993–8.
[20] Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in
patients with metabolic syndrome. Diabetes Res Clin Pract 2011, Apr 15. [Epub
ahead of print].
[21] Knowles NG, Landchild MA, Fujimoto WY, Kahn SE. Insulin and amylin release
are both diminished in ﬁrst-degree relatives of subjects with type 2 diabetes.
Diabetes Care 2002;25:292–7.[22] Warram JH,MartinBC,Krolewski AS, Soeldner JS, KahnCR. Slowglucose removal
rate and hyperinsulinemia precede the development of type II diabetes in the
offspring of diabetic parents. Ann Intern Med 1990;113:909–15.
[23] Cai RC, Wei L, Di JZ, et al. Expression of omentin in adipose tissues in obese and
type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2009; 89: 381–4.
[24] Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and
in patients with impaired glucose regulation and with newly diagnosed and
untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29–33.
[25] Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and
relationship between omentin and adiponectin concentrations in type 2
diabetes mellitus. Exp Clin Endocrinol Diabetes 2011;119:257–63.
[26] Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations
are elevated in human subjects with impaired glucose tolerance and type 2
diabetes. Diabetes Care 2006;29:2457–61.
[27] An C, Wang H, Liu X, et al. Serum retinol-binding protein 4 is elevated and
positively associated with insulin resistance in postmenopausal women.
Endocr J 2009;56:987–96.
[28] Al-Daghri NM, Al-Attas OS, Alokail M, et al. Retinol binding protein-4 is
associated with TNF-a and not insulin resistance in subjects with type 2
diabetes mellitus and coronary heart disease. Dis Markers 2009;26:135–40.
[29] Cheng X, Zhang H. Serum retinal-binding protein 4 is positively related to
insulin resistance in Chinese subjects with type 2 diabetes. Diabetes Res Clin
Pract 2009;84:58–60.
[30] Jia W, Wu H, Bao Y, et al. Association of serum retinol-binding protein 4 and
visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin
Endocrinol Metab 2007;92:3224–9.
[31] Takebayashi K, Suetsugu M, Wakabayashi S, et al. Retinol binding protein-4
levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab
2007;92:2712–9.
[32] Broch M, Vendrell J, Ricart W, et al. Circulating retinol-binding protein-4,
insulin sensitivity, insulin secretion, and insulin disposition index in obese and
nonobese subjects. Diabetes Care 2007;30:1802–6.
[33] Gao S, Li M, Wang Z, et al. Serum levels of retinol-binding protein-4 and its
association with metabolic syndrome in ﬁrst-degree relatives of type 2
diabetes mellitus. Zhonghua Yi Xue Za Zhi 2009;89:2129–33.
[34] Lihn AS, Ostergard T, Nyholm B, et al. Adiponectin expression in adipose tissue
is reduced in ﬁrst-degree relatives of type 2 diabetic patients. Am J Physiol
Endocrinol Metab 2003;284:E443–8.
[35] Pellme F, Smith U, Funahashi T, et al. Circulating adiponectin levels are
reduced in nonobese but insulin-resistant ﬁrst-degree relatives of type 2
diabetic patients. Diabetes 2003;52:1182–6.
[36] Civitarese AE, Jenkinson CP, Richardson D, et al. Adiponectin receptors gene
expression and insulin sensitivity in non-diabetic Mexican Americans with or
without a family history of type 2 diabetes. Diabetologia 2004;47:816–20.
[37] Kowalska I, Straczkowski M, Nikowska A, et al. Plasma adiponectin
concentration and tumor necrosis factor-alpha system activity in lean
non-diabetic offspring of type 2 diabetic subjects. Eur J Endocrinol
2006;154:319–24.
[38] Tesauro M, Rizza S, Iantorno M, et al. Vascular, metabolic, and inﬂammatory
abnormalities in normoglycemic offspring of patients with type 2 diabetes
mellitus. Metabolism 2007;56:413–9.
[39] Sull JW, Kim HJ, Yun JE, et al. Serum adiponectin is associated with family
history of diabetes independently of obesity and insulin resistance in healthy
Korean men and women. Eur J Endocrinol 2009;160:39–43.
[40] Liu J, Wang F, Cha Y, et al. Adiponectin levels in non-obese ﬁrst-degree
relatives of type 2 diabetes patients and non-diabetic subjects: a 5-year
follow-up study. J Int Med Res 2010;38:792–802.
[41] Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the
adipocyte protein adiponectin are decreased in parallel with reduced insulin
sensitivity during the progression to type 2 diabetes in rhesus monkeys.
Diabetes 2001;50:1126–33.
[42] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type
2diabetes: close associationwith insulin resistance andhyperinsulinemia. J Clin
Endocrinol Metab 2001;86:1930–5.
[43] Song Y, Manson JE, Tinker L, Howard BV, Kuller LH, Nathan L, et al. Insulin
sensitivity and insulin secretion determined by homeostasis model
assessment and risk of diabetes in a multiethnic cohort of women: the
Women’s Health Initiative Observational Study. Diabetes Care 2007;30:
1747–52.
